BLRX — Q2 2026 Financial Report Analysis

A brain-cancer bet funded by a shrinking cash pile

BioLineRx is no longer really a drug-selling company. In late 2024 it handed the rights to its one approved drug, APHEXDA (motixafortide, used to collect stem cells from multiple myeloma patients before a transplant), to licensing partners and now earns only a royalty on those sales. Its spending now goes into GLIX1, an experimental oral brain-cancer drug it took on in September 2025. In the second quarter of 2026 (April–June), royalty income stayed flat at $0.29 million. Research spending went up by a quarter, and the operating loss widened 55% to $3.57 million. The company ended June with $13.1 million in cash and bank deposits. It still carries a formal "going concern" warning and raised a further $3.75 million soon after the quarter closed, at a price that significantly dilutes existing shareholders.

As a foreign private issuer based in Israel, BioLineRx does not file the US 10-Q quarterly report. Its quarterly numbers come in a Form 6-K, the form foreign companies use to furnish interim reports to the SEC. This one was filed on August 31, 2026 and included the press release, unaudited interim statements and management's operating and financial review.

At a glance

• $13.1 million in cash and deposits, down from $20.9 million at the start of 2026. That is a $7.8 million drop in six months. Management still says the cash lasts "into the first half of 2027", which is only a few quarters away.
• Operating loss of $3.57 million, versus $2.30 million a year ago (+55%). The increase comes from building out GLIX1: research and development (R&D) rose 26.5% to $2.94 million.
• Loss per ADS of $0.98, versus $1.00. The small improvement in the per-share figure does not mean the business got better. It came from more shares in issue and from a partner absorbing $1.3 million of the loss (explained below).

The numbers

All figures are in US dollars, unaudited, for the three months to June 30. An ADS (American Depositary Share, the form in which the stock trades on Nasdaq) represents 600 ordinary shares.

For the first half (January–June), royalty revenue rose 38% to $0.77 million as APHEXDA sales by US licensee Ayrmid grew. The net result went from a $1.19 million profit in H1 2025 to a $6.93 million loss in H1 2026. Last year's "profit" was an accounting effect, not an operating one: it came from a $6.4 million non-cash gain when the company revalued its warrants as the share price fell.

Takeaway: BioLineRx's per-share loss looks steady only because a partner owns 60% of the GLIX1 subsidiary and is assigned 60% of its losses on paper, while BioLineRx puts up the cash. Measured in cash, the company is burning about $5.5 million every six months from operations, plus about $2.2 million in scheduled loan repayments, against $13.1 million on hand. The question that matters is whether GLIX1 produces clinical data or a partnership before the money runs out.

Where the money goes now: GLIX1

GLIX1 is a pill designed to damage cancer cells' DNA-repair machinery. The first target is glioblastoma (GBM), the most common and aggressive brain cancer, where most patients die within 18 months of diagnosis. BioLineRx does not own GLIX1 outright. It is developed inside Tetragon Biosciences, a company set up with the Norwegian biotech Hemispherian, which contributed the drug and received 60% of Tetragon's shares. In return for BioLineRx committing to invest $5 million over 36 months, it received 40% of the shares plus the deciding vote on Tetragon's board, which is why it consolidates Tetragon into its own accounts.

Progress this quarter, per the release:

• The Phase 1/2a trial (an early human study that first finds a safe dose, then looks for early signs of efficacy) began in Q1 2026. Dosing of the second of five planned dose groups started in July, and the third was expected to start in September. Three US centers are enrolling: NYU Langone, Northwestern and Moffitt. The dose-finding part is planned for up to 30 patients.
• Management described safety and tolerability so far as pleasing, about four months into the study. No efficacy data from patients has been reported yet, and a dose-escalation trial is not designed to produce any at this stage.
• In animal studies, GLIX1 slowed tumors that were resistant to temozolomide (the standard GBM chemotherapy), and it worked with PARP-inhibitor drugs in an ovarian cancer model where PARP inhibitors usually do little. On that basis the company plans to add an ovarian cancer arm to the Phase 2a part of the trial and has opened talks with PARP-inhibitor makers about possible collaborations. Animal data often does not carry over to humans, so these results are reasons to keep testing, not evidence the drug works.

Motixafortide in metastatic pancreatic cancer is still in a Phase 2b trial run by Columbia University with Regeneron's support. A pre-planned interim "futility" check, which tests whether the trial is unlikely to succeed and should stop, is still expected in 2026. The company says this program needs "minimal financial commitment" from it. The filing also warns that Gloria, its Asian partner, is "not currently advancing" a planned pancreatic cancer study in China, and "it is unclear when such study will be initiated, if at all."

What the headline numbers hide

• Most of the GLIX1 loss is booked to the partner, but BioLineRx pays for it. In Q2, $1.31 million of the $4.34 million loss was assigned to "non-controlling interests", meaning Hemispherian's 60% share of Tetragon's loss. That is why the loss attributable to BioLineRx shareholders narrowed 23% even though the total loss widened 10% and the operating loss widened 55%. The cash does not follow the same split: BioLineRx had put $4.5 million of its $5 million commitment into Tetragon by June 30 and $5.2 million by the end of August. Beyond the commitment, each additional $1 million earns it just 1 more percentage point of ownership, up to a 70% cap. Tetragon also pays Hemispherian an $80,000 monthly advisory fee for 24 months.
• The large G&A increase is mostly a one-off in last year's numbers. Q2 2025 general and administrative costs were reduced by reversing a $0.8 million bad-debt provision after Gloria paid an overdue milestone. Without that, last year's figure would have been about $1.0 million, so underlying overhead roughly held flat or edged down to $0.87 million.
• Warrant revaluations swing the bottom line. BioLineRx records some of its warrants (rights for investors to buy shares at a set price) as liabilities and revalues them each quarter as the share price moves. That added a $0.69 million non-cash charge in Q2 2026 and $1.85 million in Q2 2025, and it produced the $6.4 million gain behind last year's first-half "profit". Comparisons of net income between years are mostly noise from this. The operating loss is the better guide.
• Cash burn was helped by paying suppliers more slowly. First-half operating cash outflow ($5.50 million) was $1.4 million lower than the net loss ($6.93 million). Most of that gap comes from a $1.26 million increase in accounts payable and accruals, with trade payables up from $3.49 million to $4.29 million. That cash will have to be paid out eventually.
• About half the cash is owed to the lender. The secured loan from BlackRock (formerly Kreos) still stood at $6.70 million at June 30. Of that, $4.48 million is due within a year at 9.5% interest and it is fully repaid by December 2027. The company paid $2.24 million in principal in the first half. The loan also requires BioLineRx to keep at least $4 million in cash. Net of the debt, the cash cushion is about $6.4 million.
• Going-concern warning, and more dilution. Both management and the auditor say there is "substantial doubt" (the formal going-concern warning) about the company's ability to keep operating without new money. On August 27 BioLineRx agreed to sell 1.35 million ADSs (or equivalents) at $2.78 each, raising $3.75 million before fees. That is about 31% of the 4.37 million ADSs outstanding at June 30. The buyer also received warrants for another 2.02 million ADSs at $2.78, and older warrants it held were repriced down to $2.78 and extended to 2031. A resale registration for those warrant shares was filed in late September. By September 24 the company had 4.98 million ADSs outstanding, with warrants on another 4.03 million. A securities rule that limits share sales by small companies ("baby shelf") capped further at-the-market share sales at about $4.5 million at the time of the report.

Outlook

Management's guidance: cash "into the first half of 2027", reiterated in the same report that disclosed the August raise. Expected events: the third GLIX1 dose group starting in September, presentations at EANO (September), ESMO (October, ovarian/PARP data) and SNO (November), a decision on adding an ovarian cancer arm to Phase 2a, and the pancreatic cancer trial's interim futility analysis in 2026.

Our read: The financial picture is short-dated. Quarterly operating costs of about $3.5–4 million, loan payments of about $1.1 million a quarter and royalty income of about $0.3–0.4 million add up to a net drain of roughly $4–5 million a quarter. Against $13.1 million plus the August raise, that supports management's first-half-2027 runway and not much beyond it. On September 29 the ADSs closed at $2.36, which values the company at about $11.7 million, less than its June 30 cash balance. That suggests the market expects more dilutive financing before any GLIX1 efficacy data. The two developments most likely to change this are (1) a development deal with a PARP-inhibitor maker, which management says it is discussing but has not announced, and (2) a positive interim result in the pancreatic trial, which would give motixafortide value outside stem-cell mobilization. Without one of them, expect further equity raises through 2027 and continued dilution for existing holders. The Q3 6-K, likely in late November based on last year's timing, should show whether cash fell below about $10 million after the August raise.